The lawsuit claims that the three drugmakers participated in pay-for-delay deals to prevent the release of a generic, cheaper version of the wakefulness drug Provigil.
The settlement resolves a class-action lawsuit brought by health plans and other indirect purchasers of Provigil.
Read the full report here.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
Register to Attend Webinar
Presenters:
Joel Ray, COL, USAF, NC, MSN, RN, NEA-BC, Laudio and StaffGarden by Ascend Learning|Larissa Africa, MBA, RN, CENP, FAONL, FAAN, StaffGarden by Ascend Learning|Alicia Potolsky, DNP, RN, NE-BC, DipACLM, El Camino Health|Julie Balluck, DNP, RN, NEA-BC, Texas Health Resources
Next Up in Pharmacy
-
Children’s Hospital of Philadelphia has named Andrea DiPietro, PharmD, as associate vice president and the organization’s first chief pharmacy officer. …
-
The FDA held a public hearing Sept. 14 on the potential future therapeutic use of psychedelic drugs, gathering input on…
-
Centric Compounding has recalled six lots of injectable Glutathione, Myer’s Cocktail and Tri-Immune Boost products nationwide after they were found…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.
